Non-hodgkin Lymphoma

CAR-T cell therapy and bispecifics in the treatment of lymphoma: Updates from ASH 2022 Prof. Swaminathan Iyer (University of Texas MD Anderson Cancer Center) reviews the latest data around CAR-T cell therapy and bispecific antibodies presented at ASH 2022. Further information: Abstract 655 entitled ‘Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy […]

The role of transplant and biologics in mantle cell lymphoma In the first of two updates from ASH 2022, Swaminathan Iyer (University of Texas MD Anderson Cancer Center) provides an overview of the plenary session presented by Dr Martin Dreyling at ASH 2022, discussing the role of transplant and biologics in mantle cell lymphoma. In […]

Dr William Townsend shares the latest data from the final analysis of the phase III GALLIUM study in patients with follicular lymphoma, which used the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab plus chemotherapy . The study compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma. The abstract ‘OBINUTUZUMAB PLUS […]